/SEER
SEER Stock - Seer, Inc.
Healthcare|BiotechnologyNASDAQ
$1.79-1.65%
$0.03 (-1.65%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.17
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.56
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.97
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SEER
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.77 – $1.81
TARGET (TP)$2.06
STOP LOSS$1.65
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.60
52W High$2.50
52W Low$1.62
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $13.95M | $15.18M | $14.69M | $6.39M | $656,000 |
| Gross Profit | $6.83M | $1.45M | $384,000 | $-374,000 | $-950,000 |
| Gross Margin | 49.0% | 9.5% | 2.6% | -5.8% | -144.8% |
| Operating Income | $-100,101,000 | $-104,942,000 | $-98,043,000 | $-71,696,000 | $-33,649,000 |
| Net Income | $-86,599,000 | $-86,277,000 | $-92,966,000 | $-71,169,000 | $-32,775,000 |
| Net Margin | -620.9% | -568.3% | -633.1% | -1113.1% | -4996.2% |
| EPS | $-1.39 | $-1.35 | $-1.42 | $-1.13 | $-0.51 |
Company Overview
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
2
67%
Sell / Underperform
1
33%
Analyst Consensus🔴 Bearish
0 Bullish3 Neutral/Bearish
Price Targets
$10
Average Target
↑ 430.7% Upside
Now
$7
Low
$10
Average
$12
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 5th 2023 | JP Morgan | Resumed | Neutral | $10 |
| January 4th 2023 | BofA Securities | Downgrade | Underperform | $6.5← $9 |
| August 11th 2022 | JP Morgan | Downgrade | Neutral | $12← $20 |
Earnings History & Surprises
SEERBeat Rate
61%
Last 18 quarters
Avg Surprise
+3.4%
EPS vs Estimate
Beats / Misses
11/5
2 met exactly
Latest EPS
$-0.32
Q4 2025
EPS Surprise History
Q1 24
+20.0%
$-0.28vs$-0.35
Q2 24
-3.2%
$-0.32vs$-0.31
Q3 24
+2.8%
$-0.35vs$-0.36
Q4 24
-17.2%
$-0.34vs$-0.29
Q1 25
-9.7%
$-0.34vs$-0.31
Q2 25
+8.1%
$-0.34vs$-0.37
Q3 25
+15.4%
$-0.33vs$-0.39
Q4 25
0.0%
$-0.32vs$-0.32
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.32 | $-0.32 | 0.0% | = MET |
Q3 2025 | Aug 6, 2025 | $-0.39 | $-0.33 | +15.4% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.31 | $-0.34 | -9.7% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.29 | $-0.34 | -17.2% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.36 | $-0.35 | +2.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.31 | $-0.32 | -3.2% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.35 | $-0.28 | +20.0% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.38 | $-0.33 | +13.2% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.42 | $-0.36 | +14.3% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.38 | $-0.38 | 0.0% | = MET |
Q3 2022 | Aug 9, 2022 | $-0.39 | $-0.37 | +5.1% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.41 | $-0.38 | +7.3% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.34 | $-0.32 | +5.9% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.29 | $-0.30 | -3.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.28 | $-0.27 | +3.6% | ✓ BEAT |
Latest News
Seer Proteograph Platform Confirmed By Nature Genetics Study As Crucial For Accurate Drug Targets And Biomarkers
📈 PositiveBenzinga•Dec 1, 2025, 12:21 PM
Seer Unveils Multi-Disease Proteomics Insights Using Proteograph Platform During HUPO 2025 World Congress
📈 PositiveBenzinga•Nov 7, 2025, 12:10 PM
Seer Affirms FY2025 Sales Guidance of $17.000M-$18.000M vs $17.500M Est
➖ NeutralBenzinga•Nov 6, 2025, 09:16 PM
Seer Q3 EPS $(0.32) Misses $(0.31) Estimate, Sales $4.121M Beat $4.000M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 09:15 PM
Seer Demonstrates How Proteograph Platform Advances Disease Research at American Society of Human Genetics Meeting
📈 PositiveBenzinga•Oct 10, 2025, 11:04 AM
Seer GAAP EPS of -$0.34 beats by $0.03, revenue of $4.21M beats by $0.96M
📈 PositiveSeeking Alpha•May 13, 2025, 08:24 PM
Frequently Asked Questions about SEER
What is SEER's current stock price?
Seer, Inc. (SEER) is currently trading at $1.79 per share. The stock has moved -1.65% today.
What is the analyst price target for SEER?
No analyst price targets are currently available for this stock.
What sector is Seer, Inc. in?
Seer, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SEER's market cap?
Seer, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.
Does SEER pay dividends?
No, Seer, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANEB
Anebulo Pharmaceuticals, Inc.
$2.17
Mkt Cap: $0.1B
ANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
CCCC
C4 Therapeutics, Inc.
$2.03
Mkt Cap: $0.1B
CGEM
Cullinan Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
FHTX
Foghorn Therapeutics Inc.
$5.24
Mkt Cap: $0.3B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
GLUE
Monte Rosa Therapeutics, Inc.
$15.54
Mkt Cap: $1.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
Explore stocks similar to SEER for comparison